Seven Fleet Capital Management LP Makes New Investment in Climb Bio, Inc. $CLYM

Seven Fleet Capital Management LP acquired a new stake in Climb Bio, Inc. (NASDAQ:CLYM) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 76,400 shares of the company’s stock, valued at approximately $306,000. Seven Fleet Capital Management LP owned about 0.11% of Climb Bio as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the 1st quarter worth approximately $27,000. Goldman Sachs Group Inc. purchased a new stake in shares of Climb Bio during the first quarter valued at approximately $147,000. Marshall Wace LLP purchased a new stake in shares of Climb Bio during the second quarter valued at approximately $46,000. Qube Research & Technologies Ltd bought a new stake in Climb Bio during the second quarter worth $43,000. Finally, Jane Street Group LLC bought a new stake in Climb Bio during the second quarter worth $184,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Price Performance

Shares of CLYM stock opened at $11.45 on Friday. The company’s fifty day simple moving average is $10.33 and its two-hundred day simple moving average is $7.00. Climb Bio, Inc. has a 1 year low of $1.17 and a 1 year high of $12.48. The stock has a market capitalization of $655.63 million, a price-to-earnings ratio of -14.68 and a beta of 0.09.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. Equities research analysts anticipate that Climb Bio, Inc. will post -0.87 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Robert W. Baird set a $21.00 target price on shares of Climb Bio in a research note on Wednesday, May 6th. Wall Street Zen raised Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. BTIG Research increased their price target on Climb Bio from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Mizuho began coverage on Climb Bio in a report on Wednesday, April 15th. They issued an “outperform” rating and a $18.00 price objective for the company. Finally, Guggenheim began coverage on Climb Bio in a research note on Monday, June 8th. They issued a “buy” rating and a $35.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $21.73.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.